Primary cutaneous lymphomas (PCL) are defined as clonal proliferations of malignant T or B lymphocytes that present in the skin with no evidence of extracuta-neous disease at the time of diagnosis. They can be distinguished into cutaneous T-cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL) and the rare precursor dendritic cell neoplasms. The PCL are now classified in the new WHO-EORTC classification (Willem-ze et al. 2005; Table 14.1).
Primary cutaneous lymphomas are different from lymphomas of nodal origin in regard to clinical picture, course of disease and therapy. As there has been no curative therapy hitherto, treatment should be directed towards improvement of quality of life. Initial aggressive therapy, i.e. multi-agent chemotherapy, will in most cases result in only a transient remission and is not able to improve overall survival. Therefore an intensive search for new therapeutically active agents, which are acting specifically on the tumour cells, is ongoing. Immune therapies are of special interest as the tumour cells originate from B or T lymphocytes (Table. 14.2). For these cells a whole variety of surface antigens are well defined and monoclonal antibodies are available. In this chapter we briefly describe the
Table 14.2. Biologics in cutaneous lymphoma
Table 14.1. WHO-EORTC classification of cutaneous lymphomas with primary cutaneous manifestations
Cutaneous T-cell and NK-cell lymphomas
Mycosis fungoides variants and subtypes Folliculotropic MF Pagetoid reticulosis
• Granulomatous slack skin S£zary syndrome
Adult T-cell leukaemia/lymphoma
Primary cutaneous CD30-positive lymphoproliferative disorders
• Primary cutaneous anaplastic large cell lymphoma Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Primary cutaneous peripheral T-cell lymphoma, unspecified
• Primary cutaneous aggressive epidermotropic CD8-posi-tive T-cell lymphoma (provisional)
• Cutaneous y/8 T-cell lymphoma (provisional)
• Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (provisional)
Primary cutaneous marginal zone B-cell lymphoma Primary cutaneous follicle centre lymphoma Primary cutaneous diffuse large B-cell lymphoma, leg type Primary cutaneous diffuse large B-cell lymphoma, other intravascular large B-cell lymphoma
Precursor hematologic neoplasm
CD4+/CD56+ hematodermic neoplasm
DAB389IL-2 (Ontak) Alemtuzumab (MabCampath) 90Y-ibritumomab tiuxetan
(Zevalin) Rituximab (Mabthera) Depsipeptide (FR901228) Suberoylanilide hydroxamic acid
CD25 CD52 CD20
Histone deacetylases Histone deacetylases
Fusion protein CTCL
Monoclonal antibody CTCL
Monoclonal antibody, CBCL
chelator and radionuclide
Monoclonal antibody CBCL
Cyclic tetrapeptide CTCL
clinical picture and course of the most common cutaneous lymphomas. We also review data on treatment, efficiency and safety of biological agents currently used in the treatment of PCL.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.